Revol LIMS delivers 21 CFR Part 11 and EU GMP Annex 11-compliant electronic records and signatures, automated stability study management, pharmacopoeial method compliance (USP/EP/BP), OOS/OOT investigation workflows, and validated LIMS infrastructure aligned to GAMP 5 — in one platform built for pharmaceutical cGMP environments.
Pharmaceutical quality control laboratories operate under the strictest data integrity, electronic records, and analytical compliance requirements of any industry sector. Whether your laboratory supports drug substance (API), drug product (finished dosage form), or biological product quality control, three challenges define the regulatory environment:
In a pharmaceutical laboratory, an electronic record is only as valid as the infrastructure it was created in. Revol LIMS is built from the ground up for 21 CFR Part 11 and EU GMP Annex 11 compliance — with immutable, user-attributed, time-stamped audit trails across every data entry, review, approval, and modification event.
Pharmaceutical stability studies are one of the most operationally complex commitments a laboratory makes — spanning months to years, across multiple ICH climate zones, with regulatory consequence for every missed time-point. Revol LIMS automates the complete stability study lifecycle from protocol setup through time-point scheduling, pull management, analytical testing, and data trending.
An Out-of-Specification (OOS) result in a pharmaceutical laboratory triggers a mandatory, documented investigation process under FDA guidance (OOS Investigation Guidance, 2006) and ICH Q10 quality system requirements. Revol LIMS enforces the full Phase I and Phase II OOS investigation workflow, maintaining complete traceability of every investigative step and decision.
A pharmaceutical LIMS must maintain a living, version-controlled method library that tracks every pharmacopoeial update, internal method validation, and method transfer — ensuring every result ever released can be traced back to the exact, approved method version in use at the time of testing.
Across drug substance, drug product, and biological QC laboratories, the same recurring data integrity, analytical compliance, and operational challenges arise — and in a regulated pharmaceutical environment, the consequences are uniquely severe:
Spreadsheet-based data management with shared logins, uncontrolled Excel formulas, and no audit trail is the most common pharmaceutical laboratory data integrity finding in FDA and MHRA inspections. A single Warning Letter citing data integrity is a company-defining event.
Manual OOS investigations documented in binders or disconnected word-processing files lack the structure, completeness, and traceability that FDA OOS guidance requires — creating inspection findings that question the validity of every batch released during the affected period.
USP and EP revision cycles require ongoing method updates. When method version control is manual, outdated methods remain in use past their effective date, testing is performed against superseded specifications, and batch records cannot demonstrate that the correct method was applied.
Without automated system suitability test (SST) enforcement and instrument qualification tracking, SST failures go undetected until data review, invalidating entire analytical sequences and requiring costly re-testing and OOS-adjacent investigations.
Manual batch record review, certificate of analysis assembly from multiple data sources, and sequential paper-based approval workflows create batch release delays that impact manufacturing schedules and product supply commitments, while creating quality data gaps between testing completion and formal release.
Pharmaceutical quality control laboratories are subject to the most comprehensive and strictly enforced regulatory compliance framework of any industry. Revol LIMS is built on internationally recognised pharmaceutical regulatory frameworks, ensuring your laboratory remains continuously inspection-ready across every applicable standard.
| Standard / Regulation | How Revol LIMS Supports Compliance |
|---|---|
| 21 CFR Part 11 (FDA, US) | Fully compliant electronic records and electronic signatures: immutable audit trail, user-attributed time-stamped entries, electronic signature meaning attestation, role-based access control, and no backdoor result modification capability. Satisfies FDA inspection requirements for pharmaceutical electronic records. |
| EU GMP Annex 11 | Electronic system validation documentation, data integrity controls, backup and recovery procedures, and audit trail requirements aligned to EU GMP Annex 11 for computerised systems in pharmaceutical manufacturing and quality control. |
| EU GMP Chapter 4 (Documentation) | Document management workflows for SOPs, specifications, batch records, and analytical method documentation aligned to EU GMP Chapter 4 documentation requirements, with version control, approval workflow, and effective-date management.. |
| ICH Q10 (Pharmaceutical Quality System) | Quality system infrastructure supporting ICH Q10 requirements: CAPA management, change control, management review reporting data, deviation management, and product quality review data compilation. |
| ICH Q2(R2) (Analytical Method Validation) | Method validation data management covering accuracy, precision, linearity, specificity, detection and quantitation limits, and robustness — with structured validation reports aligned to updated ICH Q2(R2) requirements. |
| ICH Q1A / Q1B / Q1E (Stability Testing) | Stability study management aligned to ICH Q1A storage conditions, Q1B photostability requirements, and Q1E statistical analysis for shelf-life estimation — including protocol setup, time-point scheduling, trend analysis, and regulatory submission report generation. |
| USP / EP / BP / JP (Pharmacopoeial Standards) | Pharmacopoeial method library with revision tracking for USP, EP, BP, and JP — including system suitability criteria, acceptance criteria, and reference standard management aligned to current compendial requirements. |
| cGMP (21 CFR Parts 211, 212 / EU GMP Part II) | QC laboratory workflows aligned to cGMP requirements for finished pharmaceuticals (21 CFR Part 211), non-sterile bulk drugs, and API quality control (ICH Q7 / 21 CFR Part 212), including full batch record traceability and batch release documentation. |
| GAMP 5 (Computerised System Validation) | LIMS validation documentation package aligned to GAMP 5 Category 4 (Configured Products) or Category 5 (Custom Applications) as applicable, including User Requirement Specification, Functional Specification, Installation/Operational/Performance Qualification (IQ/OQ/PQ), and ongoing periodic review. |
| FDA Data Integrity Guidance (2018) | All LIMS data management practices aligned to FDA’s Data Integrity and Compliance With Drug cGMP guidance: complete and accurate contemporaneous records, attributable data, no selective reporting, and raw data preservation with full audit traceability. |
| ALCOA+ Data Integrity | All pharmaceutical analytical data is Attributable, Legible, Contemporaneous, Original, and Accurate — with the additional ALCOA+ attributes of Complete, Consistent, Enduring, and Available — satisfying global regulatory inspectors across FDA, EMA, MHRA, PMDA, and TGA jurisdictions. |
Tracks every pharmaceutical sample — raw material, in-process, finished product, stability, reference standard — with full cGMP-compliant traceability from receipt through testing, review, approval, and retention.
Manages the complete stability study lifecycle from ICH-aligned protocol setup through automated time-point scheduling, pull management, analytical testing, trending, and regulatory submission report generation.
Enforces the complete FDA OOS guidance-aligned investigation workflow — from automatic flag generation through Phase I and II investigation, re-testing authorisation, batch disposition, and CAPA closure.
Maintains a version-controlled method library with pharmacopoeial revision tracking, validation data management, and system suitability enforcement — ensuring every result is traceable to the approved method in use at the time of testing.
Connects to pharmaceutical QC instruments with bi-directional data transfer, automated SST enforcement, and instrument qualification record management — eliminating manual transcription and qualification documentation gaps.
Manages the complete electronic batch release process — from result review through multilevel approval to CoA generation — with electronic signatures, full audit trail, and configurable release hold workflows for pending investigations.
| Feature | Revol LIMS | Legacy Vendors |
|---|---|---|
| 21 CFR Part 11 / Annex 11 | Built-in — immutable audit trail, electronic signatures, role-based access, and no backdoor modification — inspection-ready from day one. | Hours of manual assembly per batch from instrument exports, spreadsheets, and multiple systems. |
| OOS Investigation | Automated — flag generation with enforced Phase I/II investigation workflows, re-testing authorisation, and CAPA linkage. | Partial traceability requiring manual cross-referencing across production records, spreadsheets, and ERP exports. |
| Stability Management | Automated — ICH-aligned time-point scheduling, advance pull alerts, real-time trending, and regulatory submission reports. | External SPC tools or spreadsheets with no automatic integration to test results; patterns visible only retrospectively. |
| Pharmacopoeial Methods | Version-controlled — method library with pharmacopoeial revision tracking and SST enforcement per analytical run. | Managed in spreadsheets or binders; specification changes require manual updates across every relevant document. |
| Instrument Integration | Pre-configured IQ/OQ/PQ — validation documentation package aligned to GAMP 5 Category 4/5 requirements, reducing validation effort significantly. | Third-party middleware or manual CSV uploads for most instrument types; per-instrument development often required. |
| Implementation Time | 3–4 Months: Rapid deployment with pharmaceutical regulatory domain expertise and a pre-built CSV package. | 12–18 Months: Protracted timelines compounded by validation, custom configuration, and change control requirements. |
Revol LIMS gives pharmaceutical quality control laboratories the validated, inspection-ready infrastructure to manage stability studies, enforce OOS investigations, maintain pharmacopoeial method compliance, and release batches with complete 21 CFR Part 11 and EU GMP Annex 11 compliant data integrity — without adding administrative burden.
“Ready to modernise your laboratory operations? Book your FREE no-obligation demo today.”
Yes. Revol LIMS is built from the ground up for 21 CFR Part 11 and EU GMP Annex 11 compliance. The system provides an immutable, user-attributed, time-stamped audit trail for every data entry, modification, review, approval, and deletion event. Electronic signatures carry meaning attestation and are equivalent to handwritten signatures for batch release purposes. Role-based access control, password policy enforcement, and no backdoor or administrative override for result modification without audit capture are all standard features — not optional configurations.
Yes. Revol LIMS manages the complete stability study lifecycle from ICH Q1A-aligned protocol setup through automated time-point scheduling, advance pull alerts, pull management, analytical testing, real-time acceptance criteria trending, and out-of-trend (OOT) flagging. Stability study summary reports suitable for regulatory submission and annual product review (APR/PQR) compilation are generated automatically from the confirmed stability dataset.
Yes. Revol LIMS automatically flags every Out-of-Specification result at entry and mandates the initiation of a Phase I laboratory investigation before any further action can be taken. Phase I checklists, Phase II full investigation assignment, re-testing and re-sampling authorisation with supervisor approval, CAPA linkage, and investigation closure documentation are all enforced within the system workflow — producing a complete, FDA-inspection-ready OOS investigation file for every occurrence.
Yes. Revol LIMS maintains a version-controlled pharmacopoeial method library covering USP, EP, BP, and JP, with effective-date management, approver attribution, and superseded version archiving. Every analytical result is linked to the exact method version in use at the time of testing, providing complete traceability for batch records and regulatory submissions. System Suitability Test acceptance criteria are enforced per analytical run against the current approved method version.
Revol LIMS is supplied with a pre-configured Computer System Validation (CSV) documentation package aligned to GAMP 5 Category 4 (Configured Product) requirements, including User Requirement Specification (URS), Functional Risk Assessment, Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) protocols and reports. This significantly reduces the validation effort compared to building from scratch, and Revol’s implementation team provides dedicated CSV support for pharmaceutical client deployments.
Yes. Revol LIMS includes a configurable multilevel electronic batch release workflow with electronic signatures, supporting QP review and certification of batch records prior to release of medicinal products for sale in the EU. Batch disposition (Release / Hold / Reject) is captured with mandatory justification, open OOS investigations trigger configurable batch release holds, and the complete batch release data package including CoA and analytical data is generated and archived with full audit trail.
